NDAORALTABLETPriority Review
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
PERMAX (pergolide mesylate) by Bausch + Lomb is clinical pharmacology pharmacodynamic information pergolide is a potent dopamine receptor agonist. First approved in 1988.
Drug data last refreshed 49m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERMAX (pergolide mesylate) is an oral dopamine receptor agonist approximately 10–1000 times more potent than bromocriptine on a milligram basis. It is indicated for Parkinson's disease, where it stimulates postsynaptic dopamine receptors in the nigrostriatal system to improve motor symptoms. The drug is absorbed orally with significant renal excretion and undergoes extensive hepatic metabolism.
LOE Approaching
Declining product lifecycle with low competitive pressure (30%) signals preparation for loss of exclusivity and potential consolidation of commercial headcount.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamic Information Pergolide is a potent dopamine receptor agonist. Pergolide is 10 to 1000 times more potent than bromocriptine on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide inhibits the secretion of prolactin in humans;…
Indications
Worked on PERMAX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.